Abstract
In the context of the transition to a common market for medicinal products within the framework of the Eurasian Economic Union (EAEU) and further har monization of national legislation with supranational requirements, assessment of the impact of regulatory framework updates on the development of the Rus sian pharmaceutical sector is of great importance. A sequential analysis of cur rent regulatory legal acts was carried out. Key provisions approved by the new documents that entered into force in the Russian Federation in early 2026 in connection with the transition to the common market for medicinal products in the EAEU include extension of the validity of national registration certifi cates, transition to the unified registration rules in the EAEU, and regulation of the manufacturing and circulation of individual biotechnological medicinal products. These regulatory changes are aimed at creating a balanced system of circulation of medicinal products, on the one hand, ensuring the continuity of the supply of medicinal products to the population and minimizing the risk of shortages of these products, and, on the other hand, improving their quality and safety. Of particular importance is the development of regulatory frame work for personalized medicine, which opens up new opportunities for the treat ment of serious diseases using innovative technologies.